Laurence Lytton Takes 1.3M Share Stake in NeuroOne Medical (NMTC)

Ticker: NMTC · Form: SC 13G · Filed: Jan 11, 2024 · CIK: 1500198

Neuroone Medical Technologies CORP SC 13G Filing Summary
FieldDetail
CompanyNeuroone Medical Technologies CORP (NMTC)
Form TypeSC 13G
Filed DateJan 11, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: insider-ownership, beneficial-ownership, institutional-filing

TL;DR

**Laurence Lytton just disclosed a big 1.3M share position in NMTC, signaling a notable individual bet.**

AI Summary

Laurence W. Lytton, an individual investor, has reported beneficial ownership of 1,304,102 shares of NeuroOne Medical Technologies Corp. (NMTC) common stock as of December 28, 2023. This represents a significant stake, giving him sole voting and dispositive power over these shares. This matters to investors because a large individual holding can signal confidence in the company's future, but also means a single person has substantial influence over voting matters.

Why It Matters

A substantial individual stake like this can influence corporate governance and potentially impact stock price through future buying or selling activity.

Risk Assessment

Risk Level: medium — While a large individual stake can be a vote of confidence, it also concentrates power, meaning a single person's decisions could significantly impact the company.

Analyst Insight

Investors should monitor future filings by Laurence W. Lytton for any changes in his ownership, as a significant increase or decrease could signal a shift in his confidence in NeuroOne Medical Technologies Corp. and potentially impact the stock price.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

Who is the reporting person in this SC 13G filing?

The reporting person is Laurence W. Lytton, as stated in Item 1 of the Schedule 13G.

What is the name of the issuer whose securities are being reported?

The issuer is NeuroOne Medical Technologies Corporation, as identified in the 'Name of Issuer' section of the filing.

How many shares of NeuroOne Medical Technologies Corp. does Laurence W. Lytton beneficially own with sole voting power?

Laurence W. Lytton beneficially owns 1,304,102 shares with sole voting power, as reported in Item 5 of the Schedule 13G.

What was the date of the event that required this Schedule 13G filing?

The date of the event which required the filing of this statement was December 28, 2023, as indicated on the cover page.

Under which rule was this Schedule 13G filed?

This Schedule 13G was filed under Rule 13d-1(c), as marked with an 'X' on the cover page.

Filing Stats: 911 words · 4 min read · ~3 pages · Grade level 6.9 · Accepted 2024-01-11 13:04:48

Key Financial Figures

Filing Documents

Ownership

Item 4. Ownership. See Items 5-9 and 11 of the cover page. The percentages reported in this Schedule 13G are based on 25,311,404 shares of Common Stock outstanding as of January 3, 2024, as reported in the Prospectus Supplement filed by the Issuer on January 5, 2024.

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Certification

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated:January 11, 2024 /s/ Laurence W. LyttonI Laurence W. Lytton

View Full Filing

View this SC 13G filing on SEC EDGAR

View on Read The Filing